Ignite Creation Date:
2025-12-25 @ 4:42 AM
Ignite Modification Date:
2026-06-18 @ 4:33 PM
Study NCT ID:
NCT02254018
Status:
COMPLETED
Last Update Posted:
2023-10-24
First Post:
2014-09-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
Sponsor:
Boehringer Ingelheim
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Head and Neck Neoplasms | View |
Keywords: